Core Viewpoint - Hongli Medical Management (09906) reported a total revenue of 769 million yuan for the fiscal year 2024, representing a year-on-year growth of 1.04%, while the net profit attributable to shareholders decreased by 18.69% to 31.15 million yuan [2] Financial Performance - Total revenue for 2024 was 769 million yuan, with a year-on-year increase of 1.04% [2] - Net profit attributable to shareholders was 31.15 million yuan, down 18.69% compared to the previous year [2] - Operating cash flow net amount was 83.34 million yuan, a decrease of 8.97% year-on-year [24] - Basic earnings per share were 0.06 yuan, and the weighted average return on equity was 5.53%, down 1.44 percentage points from the previous year [2][20] Valuation Metrics - As of April 29, the price-to-earnings ratio (TTM) was approximately 27.47 times, the price-to-book ratio (TTM) was about 1.49 times, and the price-to-sales ratio (TTM) was around 1.11 times [2] Revenue Composition - Revenue composition for 2024 included: - Comprehensive medical services: 456.4 million yuan - Pharmaceutical sales: 308.9 million yuan - Postpartum care services: 3.4 million yuan [16] Asset and Liability Changes - As of the end of 2024, accounts receivable increased by 101.48%, while the proportion of right-of-use assets decreased by 28% [35] - Long-term borrowings decreased by 42.75%, and accounts payable decreased by 19.12% [38] - The current ratio was 1.01, and the quick ratio was 0.91 [42]